The features and efficiency of therapy for uncomplicated cystitis in pregnant women and puerperas


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To investigate the features of therapy and to evaluate its efficiency for acute uncomplicated cystitis in pregnant women andpuerperas. Matetials and methods. The investigation enrolled 46 pregnant women and 10 puerperas with acute uncomplicated cystitis. All the patients underwent clinical and laboratory examination and received therapy with fosfomycin trometamol at a single 3-g dose. Results. Fosfomycin demonstrated a significant efficacy: there was regression of clinical symptoms in 96.4% of the patients and complete pathogen elimination in 94.6%; there were no recurrent cystitis at a 3-month follow-up after therapy. Neither side effects nor adverse reactions were found; a high compliance to therapy was noted. Conclusion. The first-line empirical treatment of acute uncomplicated cystitis in pregnant women and puerperas is single-dose fosfomycin trometamol that exceeds antibacterial drugs in a long-term dosage regimen in terms of convenience of use.

全文:

受限制的访问

作者简介

Vladimir Serov

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: v_serov@oparina4.ru
MD, professor, academician of the Russian Academy of Sciences, chief researcher

Anna Balushkina

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: ann.balushkina@gmail.com
PhD, researcher

Victor Tyutyunnik

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: tioutiounnik@mail.ru
MD, professor, the head of the Obstetric Physiological Department

Natalia Kan

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: kan-med@mail.ru
MD, professor, Department of Obstetrics and Gynecology

参考

  1. Kalinderi K., Delkos D., Kalinderis M., Athanasiadis A., Kalogiannidis I. Urinary tract infection during pregnancy: current concepts on a common multifaceted problem. J. Obstet. Gynaecol. 2018; 38(4): 448-53. https://dx.doi.org/10.1080/ 01443615.2017.1370579.
  2. Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю. Урология. Клинические рекомендации. М.: ГЭОТАР-Медиа; 2016.
  3. Flores-Mireles A.L., Walker J.N., Caparon M., Hultgren S.J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 2015; 13(5): 269-84. https://dx.doi.org/10.1038/nrmicro3432.
  4. Matuszkiewicz-Rowinska J., Mafyszko J., Wieliczko M. Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems. Arch. Med. Sci. 2015; 11(1): 67-77. https://dx.doi.org/10.5114/aoms.2013.39202.
  5. Перепанова Т.С. Федеральные клинические рекомендации 2015. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Терапевтический архив. 2016; 88(4): 100-4.
  6. Grabe M., Bartoletti R., Bjerklund Johansen T.E., Cai T., Qek M., Koves B. et al. Guidelines on urological infections. European Association of Urology; 2015. 86 p.
  7. Kim H.Y., LeeS.J., LeeD.S., Yoo J.M., Choe H.S. Microbiological characteristics of unresolved acute uncomplicated cystitis. Microb. Drug Resist. 2016; 22(5): 387-91. https://dx.doi.org/10.1089/mdr.2015.0241.
  8. Grigoryan L., Trautner B.W., Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA. 2014; 312(16): 167784. https://dx.doi.org/10.1001/jama.2014.12842.
  9. Marshall K., Hale D. Urinary tract infections. Home Healthc. Now. 2017; 35(8): 448-9. https://dx.doi.org/10.1097/NHH.0000000000000597
  10. Barros B.S. Antibiotic treatment for uncomplicated urinary tract infections. JAMA. 2018; 320(12): 1284. https://dx.doi.org/10.1001/jama.2018.10011.
  11. Yang B., Yang F., Wang S., Wang Q., Liu Z., Feng W. et al. Analysis of the spectrum and antibiotic resistance of uropathogens in outpatients at a tertiary hospital. J. Chemother. 2018; 30(3): 145-9. https://dx.doi.org/10.1080/11200 09X.2017.1418646.
  12. Arana D.M., Rubio M., Aids J. Evolution of antibiotic multiresistance in Escherichia coli and Klebsiella pneumoniae isolates from urinary tract infections: A 12-year analysis (2003-2014). Enferm. Infecc. Microbiol. Clin. 2017; 35(5): 293-8. https://dx.doi.org/10.1016/ j.eimc.2016.02.018.
  13. Lee D.S., Lee S.J., Choe H.S. Community-acquired urinary tract infection by Escherichia coli in the era of antibiotic resistance. Biomed. Res. Int. 2018; 2018: 7656752. https://dx.doi.org/10.1155/2018/7656752. eCollection 2018.
  14. Bader M.S., Loeb M., Brooks A.A. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad. Med. 2017; 129(2): 242-58. https://dx.doi.org/10.1080/00325481.2017.1246055.
  15. Лисицына О.И. Фосфомицин в лечении острого неосложненного цистита. Взгляд акушера-гинеколога. Акушерство и гинекология. 2019; 2: 165-9.
  16. Zhanel G.G., Walkty A.J., Karlowsky J.A. Fosfomycin: a first-line oral therapy for acute uncomplicated cystitis. Can. J. Infect. Dis. Med. Microbiol. 2016; 2016: 2082693. https://dx.doi.org/10.1155/2016/2082693.
  17. Mannucci C., Dante G., Miroddi M., Facchinetti F., D’Anna R., Santamaria A. et al. Vigilance on use of drugs, herbal products, and food supplements during pregnancy: focus on fosfomycin. J. Matern. Fetal Neonatal Med. 2019; 32(1): 125-8. https://dx.doi.org/10.1080/14767058.2017.1373761.
  18. Kranz J., Schmidt S., Leber C., Schneidewind L., Mandraka F., Kunze M. et al. The 2017 Update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients. Part II: Therapy and prevention. Urol. Int. 2018; 100(3): 271-8. https://dx.doi.org/10.1159/000487645.
  19. Matthews P.C., Barrett L.K., Warren S., Stoesser N., Snelling M., Scarborough M., Jones N. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infect. Dis. 2016; 16(1): 556. https://dx.doi.org/10.1186/ s12879-016-1888-1.
  20. Raz R. Fosfomycin: an old-new antibiotic. Clin. Microbiol. Infect. 2012; 18(1): 4-7. https://dx.doi.org/10.1111/j.1469-0691.2011.03636.x.
  21. Cho Y.H., Jung S.I., Chung H.S., Yu H.S., Hwang E.C., Kim S.O. et al. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. Int. Urol. Nephrol. 2015; 47(7): 1059-66. https://dx.doi.org/10.1007/s11255-015-1018-9.
  22. Sultan A., Rizvi M., Khan F., Sami H., Shukla I., Khan H.M. Increasing antimicrobial resistance among uropathogens: is fosfomycin the answer? Urol. Ann. 2015; 7(1): 26-30. https://dx.doi.o^/10.4103/0974-7796.148585.
  23. Rosso-Fernandez C., Sojo-Dorado J., Barriga A., Lavin-Alconero L., Palacios Z., Ldpez-Hernandez I. et al.; FOREST Study Group. Fosfomycin versus merope-nem in bacteraemic urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. BMJ Open. 2015; 5(3): e007363. https://dx.doi.org/10.1136/bmjopen-2014-007363.
  24. Reffert J.L., Smith W.J. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2014; 34(8): 845-57. https://dx.doi.org/10.1002/phar.1434.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2019
##common.cookie##